MedTrace Logo

Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

NCT05845723 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2024-08-19

No results posted yet for this study

Summary

This project aims to evaluate the efficacy and safety of the combination of glucocorticoids with tocilizumab or tofacitinib, compared to the traditional combination of glucocorticoids with cyclophosphamide in the treatment of vascular Behçet's syndrome.

Conditions

  • Aneurysm
  • Behcet Syndrome, Vascular Type

Interventions

DRUG

tocilizumab

Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.

DRUG

tofacitinib

Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.

DRUG

cyclophosphamide

Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2026-06-01
Completion
2027-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05845723 on ClinicalTrials.gov